Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00547659 effects on cerebrospinal fluid lymphocytes in anti-TNF inadequate responder Crohn's disease or ulcerative colitis
NL-OMON39430Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of ontamalimab in Crohn's disease and autoimmune colitis (2 cohorts), sponsored by Pfizer. Started Oct 2012; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON39430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39430.